PRIA Logo™
HR6789119th Congress

Federal Prisons Naloxone Access Act of 2025

Sponsored By: Representative Foushee, Valerie P. [D-NC-4]

Introduced

Summary

Requires federal prisons to stock and make accessible opioid antagonists like naloxone. This bill would direct the Bureau of Prisons to create a program that keeps overdose‑reversal kits on site, trains people to use them, documents uses, and reports to Congress on supply and outcomes.

Show full summary
  • People in custody: Incarcerated individuals would be able to access and use opioid antagonist kits to respond to overdoses and receive annual training on overdose recognition and administration.
  • Facility staff and operations: Facilities would be required to place and securely store kits in many common areas, check expirations regularly, and provide annual training for personnel. The bill also offers liability protection for incarcerated people who administer a kit in good faith.
  • Oversight and reporting: The Bureau must document every administration and send an annual report to Congress with counts of kits, overdoses, trainings, and expired kits, and the statute defines covered terms and personnel.

*The bill would authorize $6.0 million for fiscal year 2026 and $2.0 million each for fiscal years 2027 and 2028, increasing federal spending by about $10.0 million over those years.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Naloxone access and training in prisons

If enacted, the bill would require the Bureau of Prisons to keep enough opioid antagonist (naloxone) kits at every federal prison. Kits would be placed in many spots, like medical units, visiting areas, housing, dining halls, work and recreation spaces, hallways, and education and religious areas. Kits must be stored at room temperature, out of direct sunlight, and in secure locations accessible to staff. Incarcerated people would be allowed to access kits and use them on someone who is overdosing. Bureau medical staff would give annual training to personnel and incarcerated people on overdose signs and kit use. Each administration would be recorded with location, time, recipient name, and administrator name/title and recipient status. The bill would protect incarcerated people from liability if they use a kit in good faith and would define key terms like “opioid antagonist” and “opioid overdose prevention kit.”

Prison naloxone funding and reports

If enacted, the bill would authorize $6,000,000 for fiscal year 2026 and $2,000,000 for each of fiscal years 2027 and 2028 for the Bureau of Prisons to buy opioid antagonists, train people, maintain kits, and prepare reports. This is an authorization; Congress would still need to appropriate the money. The Director would also have to send Congress a yearly report for each facility showing how many antagonist doses are available, how many overdoses occurred, how many trainings were done, and how many kits expired.

Sponsors & CoSponsors

Sponsor

Foushee, Valerie P. [D-NC-4]

NC • D

Cosponsors

  • Rep. McBath, Lucy [D-GA-6]

    GA • D

    Sponsored 12/17/2025

  • Rep. Johnson, Henry C. "Hank" [D-GA-4]

    GA • D

    Sponsored 12/17/2025

  • Rep. Goldman, Daniel S. [D-NY-10]

    NY • D

    Sponsored 1/8/2026

  • Rep. Lee, Summer L. [D-PA-12]

    PA • D

    Sponsored 1/12/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation